Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study

Daniel J. Skiest, Calvin Cohen, Homayoon Khanlou, Edwin Dejesus, Thanes Vanig, Marc Tribble, Andrew Petroll, Hannah Olivet, Karam Mounzer, Robert Corales, Frank Rhame, Nicholaos Bellos, Jane Garb

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objectives: To determine if switching virologically suppressed patients on a regimen containing lopinavir/r (LPV/r) or fosamprenavir (FPV/r) to darunavir/r (DRV/r) or atazanavir/r (ATV/r) results in improved TGs while maintaining virological suppression. Methods: Eligibility criteria were undetectable HIV RNA ≥12 weeks, no PI resistance, receiving LPV/r (n = 46) or FPV/r (n = 3) plus nucleosides, and fasting TGs >200 mg/dl. Patients were randomized to either QD ATV/r or DRV/r (maintaining the same nucleosides). Primary endpoint was change in TGs from baseline to week 24. Results: 66 were screened, 51 enrolled and two withdrew consent after randomization. 24 patients received ATV/r; 25 received DRV/r. Baseline mean CD4 cell count was 569; HIV RNA was <50 copies/mL in 88% of subjects. Mean baseline TGs were 326 mg/dl in ATV/r arm and 342 mg/dl in DRV/r arm. TGs declined from baseline to week 24 by 108 mg/dl (p < 0.001) with a non-significant difference by arm: -88 mg/dl in the ATV/r arm and -126 mg/dl in the DRV/r arm. At week 24, 55% of ATV/r and 48% of DRV/r subjects had TGs <200 mg/dl (OR 1.3; Difference 7%, 95% CI: -22% to 35%). Total and HDL cholesterol decreased and LDL increased (non-significantly). Baseline quality of life (QOL) was 83% and remained high at week 24 (84%). No differences between the groups in CD4 cell counts or HIV RNA levels were noted. Conclusions: Patients with high TGs who switched from LPV/r or FPV/r to DRV/r or ATV/r had improved TGs, while maintaining virological suppression and high adherence and QOL.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalHIV and AIDS Review
Volume11
Issue number4
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Keywords

  • Antiretroviral therapy
  • HIV
  • Hyperlipidemia
  • Hypertriglyceridemia

Fingerprint Dive into the research topics of 'Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study'. Together they form a unique fingerprint.

Cite this